Untargeted metabolomics and lipidomics identified four subtypes of small cell lung cancer
Authors:
- 27 December 2022
- journal article
- research article
- Published by Springer Nature in Metabolomics
- Vol. 19 (1) , 1-10
Abstract
Introduction Small cell lung cancer (SCLC) is a heterogeneous malignancy with dismal prognosis. However, few studies have conducted on the metabolic heterogeneity in SCLC. Objective We therefore identify SCLC classifications using untargeted metabolomics and lipidomics. We also compared their survival and the immunotherapy responses. Methods Liquid Chromatography–Mass Spectrometry/Mass Spectrometry (LC–MS/MS) analysis was performed in 191 SCLC serum samples. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was conducted to identify metabolic pathways. The Kaplan–Meier and log-rank test were used to analyze the survival curves. The univariate and multivariate Cox proportional hazards regression models were used to evaluate prognostic factors for OS in patients with SCLC. Results Distinct subtypes of SCLC were identified by consensus clustering algorithm using partioning around medoids (pam) based on untargeted metabolomics and lipidomics. Four distinct subtypes of SCLC were identified, with distinct metabolic pathways. Subgroup 2 had the longest survival whereas Subgroup 1 had the shortest. Subtype 2 benefited most from immunotherapy in OS, as in contrast to Subtype 3 with shortest survival. Conclusion Our study revealed the metabolic heterogeneity in SCLC and identified four subtypes with distinct metabolic features. It indicates promising therapeutic and prognostic value that may guide treatment for SCLC. The subtype-specific clinical trials may be designed and would be instructive for drug development.Keywords
Funding Information
- Taishan Scholar Foundation of Shandong Province (tsqn201812149)
- Academic promotion program of Shandong First Medical University (2019RC004)
This publication has 29 references indexed in Scilit:
- Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung CancerPLOS Genetics, 2016
- Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancerClinical and Translational Oncology, 2016
- The Emerging Hallmarks of Cancer MetabolismCell Metabolism, 2016
- Metabolic reprogramming: the emerging concept and associated therapeutic strategiesJournal of Experimental & Clinical Cancer Research, 2015
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- Cellular Fatty Acid Metabolism and CancerCell Metabolism, 2013
- EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle RegulationJournal of Thoracic Oncology, 2013
- Small-cell lung cancerThe Lancet, 2011
- GALACTOSE CONSUMPTION AND METABOLISM IN RELATION TO THE RISK OF OVARIAN CANCERThe Lancet, 1989
- SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCERThe Lancet, 1982